Also trades as: LFMD (NASDAQ) · $vol 2M
LFMDP NASDAQ
LifeMD, Inc.
1W: +0.6%
1M: -3.2%
3M: -1.4%
YTD: +0.0%
1Y: -2.8%
3Y: +50.8%
$22.74
-0.40 (-1.75%)
Weekly Expected Move ±2.4%
$22
$22
$23
$23
$24
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (28)
Bank of America Corp DE Buys New Stake in LifeMD, Inc. $LFMD
LifeMD, Inc. 8.875% CUM PFD A declares $0.5547 dividend
HC Wainwright Comments on LifeMD’s Q3 Earnings (NASDAQ:LFMD)
UPDATE - LifeMD Reports Second Quarter 2026 Results
LifeMD Reports Second Quarter 2026 Results
LifeMD, Inc. (NASDAQ:LFMD) Receives Average Rating of “Moderate Buy” from Analysts
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
LifeMD to Participate in Upcoming Investor Conferences
Lifemd reaffirms 2026 guidance of $220M-$230M revenue and $12M-$17M adjusted EBITDA as it targets $250M+ run-rate revenue by Q4
LifeMD Reports First Quarter 2026 Results
LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of “Moderate Buy” by Brokerages
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD (NASDAQ:LFMD) Trading Down 4.2% – What’s Next?
LifeMD, Inc. 8.875% CUM PFD A declares $0.5547 dividend
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD (NASDAQ:LFMDP) Shares Up 0.1% – Time to Buy?
LifeMD, Inc. (NASDAQ:LFMD) Given Average Recommendation of “Moderate Buy” by Brokerages
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
HC Wainwright Issues Positive Forecast for LifeMD Earnings
LifeMD outlines $250M+ annualized revenue run rate target by Q4 2026 amid record GLP-1 demand and expanded partnerships
LifeMD Reports Fourth Quarter and Full Year 2025 Results
LifeMD Reports Fourth Quarter and Full Year 2025 Results
LifeMD to Participate in Two Investor Conferences During March
LifeMD to Participate in Two Investor Conferences During March
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD (NASDAQ:LFMDP) Trading 0.5% Higher – Time to Buy?